Trial Profile
MK0476 [montelukast] phase III double-blind comparative study - allergic rhinitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Montelukast (Primary) ; Pranlukast
- Indications Seasonal allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 17 Sep 2008 Actual patient number (1375) added as reported by ClinicalTrials.gov.
- 17 Sep 2008 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 17 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.